[go: up one dir, main page]

BR9906373A - Compostos pirimidinona, composições farmacêuticas contendo os compostos e processos para a preparação dos mesmos - Google Patents

Compostos pirimidinona, composições farmacêuticas contendo os compostos e processos para a preparação dos mesmos

Info

Publication number
BR9906373A
BR9906373A BR9906373-5A BR9906373A BR9906373A BR 9906373 A BR9906373 A BR 9906373A BR 9906373 A BR9906373 A BR 9906373A BR 9906373 A BR9906373 A BR 9906373A
Authority
BR
Brazil
Prior art keywords
compounds
processes
pharmaceutical compositions
compositions containing
pyrimidinone
Prior art date
Application number
BR9906373-5A
Other languages
English (en)
Other versions
BR9906373B1 (pt
Inventor
Jae-Hyoung Lee
Kyung-Jin Jang
Byoung-Wug Yoo
Ji-Han Kim
Jae-Seog Kang
Sang-Lin Kim
Original Assignee
Boryung Pharm
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=19536698&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9906373(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boryung Pharm filed Critical Boryung Pharm
Publication of BR9906373A publication Critical patent/BR9906373A/pt
Publication of BR9906373B1 publication Critical patent/BR9906373B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C07D239/36—One oxygen atom as doubly bound oxygen atom or as unsubstituted hydroxy radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Resumo da Patente de Invenção para <B>"COMPOSTOS PIRIMIDINONA, COMPOSIçõES FARMACêUTICAS CONTENDO OS COMPOSTOS E PROCESSOS PARA A PREPARAçãO DOS MESMOS"<D> A presente invenção se refere a novos compostos pirimidinona e os sais farmaceuticamente aceitáveis deles possuindo considerável ação antagónica contra o receptor angiotensina II, por isto, sendo útil no tratamento das doenças cardiovasculares causadas por ligação da angiotensina II ao seu receptor.
BRPI9906373-5A 1998-04-25 1999-04-26 compostos pirimidinona, composições farmacêuticas contendo os compostos e processos para a preparação dos mesmos. BR9906373B1 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1019980014821A KR19990081093A (ko) 1998-04-25 1998-04-25 피리미디논 화합물, 이를 함유하는 약제학적 조성물 및 이의제조방법
PCT/KR1999/000198 WO1999055681A1 (en) 1998-04-25 1999-04-26 Pyrimidinone compounds, pharmaceutical compositions containing the compounds and the process for preparing the same

Publications (2)

Publication Number Publication Date
BR9906373A true BR9906373A (pt) 2000-07-11
BR9906373B1 BR9906373B1 (pt) 2010-11-16

Family

ID=19536698

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI9906373-5A BR9906373B1 (pt) 1998-04-25 1999-04-26 compostos pirimidinona, composições farmacêuticas contendo os compostos e processos para a preparação dos mesmos.

Country Status (13)

Country Link
US (1) US6294542B1 (pt)
EP (1) EP0991627B1 (pt)
JP (1) JP3351539B2 (pt)
KR (2) KR19990081093A (pt)
CN (1) CN1195741C (pt)
AU (1) AU753424B2 (pt)
BR (1) BR9906373B1 (pt)
CA (1) CA2295446C (pt)
DE (1) DE69909209T2 (pt)
ES (1) ES2209421T3 (pt)
ID (1) ID29295A (pt)
RU (1) RU2233278C9 (pt)
WO (1) WO1999055681A1 (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100617953B1 (ko) * 2000-03-23 2006-08-30 보령제약 주식회사 피리미디논 화합물 및 이의 염의 제조방법
US7309788B2 (en) * 2001-09-21 2007-12-18 Boryung Pharmaceutical Co., Ltd. Method for preparing pyrimidinone compound and pharmaceutically acceptable salts thereof
KR100521980B1 (ko) * 2002-10-10 2005-10-17 보령제약 주식회사 피리미디논 화합물 및 이의 염의 삼수화물의 제조 방법
CN104610164B (zh) * 2010-01-21 2018-03-16 保宁制药株式会社 2‑(2‑正丁基‑4‑羟基‑6‑甲基‑嘧啶‑5‑基)‑n,n‑二甲基乙酰胺的制备方法
US8765776B2 (en) * 2011-04-12 2014-07-01 Boryung Pharmaceutical Co., Ltd. Antihypertensive pharmaceutical composition
KR101490329B1 (ko) * 2012-10-12 2015-02-04 보령제약 주식회사 피마살탄 포타슘염의 일수화물 결정, 그 제조방법, 및 그를 포함하는 약제학적 조성물
KR20170006938A (ko) 2015-07-10 2017-01-18 보령제약 주식회사 만성 신부전의 예방 또는 치료용 조성물
CN105061405A (zh) * 2015-08-04 2015-11-18 合肥创新医药技术有限公司 非马沙坦钾盐三水合物的制备方法
KR102233673B1 (ko) 2016-01-27 2021-03-30 보령제약 주식회사 당뇨병성 신장질환의 예방 또는 치료용 약학적 조성물
CN105837514B (zh) * 2016-01-29 2018-09-18 北京睿创康泰医药研究院有限公司 非马沙坦药物杂质的制备方法
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists
KR101984121B1 (ko) * 2017-08-21 2019-05-30 보령제약 주식회사 피리미디논 유도체 화합물 및 이의 용도
KR102201396B1 (ko) 2017-11-30 2021-01-11 보령제약 주식회사 피마살탄을 포함하는 약학적 조성물
KR102078691B1 (ko) 2017-11-30 2020-02-19 보령제약 주식회사 피마살탄을 포함하는 고체 분산체
KR20200073676A (ko) 2018-12-14 2020-06-24 엠에프씨 주식회사 발사탄 및 사쿠비트릴을 포함하는 고체 분산체 및 이를 포함하는 약학 조성물 및 이의 제조 방법
CN109485640B (zh) * 2018-12-24 2021-03-26 合肥创新医药技术有限公司 一种非马沙坦杂质的制备方法
CN112876424B (zh) * 2019-11-29 2023-06-30 上海拓界生物医药科技有限公司 血管紧张素ii受体及内皮素受体双重拮抗剂
KR102221856B1 (ko) 2020-10-12 2021-03-02 유니셀랩 주식회사 신규한 피마살탄 결정형의 다형체
KR20220154987A (ko) 2021-05-14 2022-11-22 주식회사 보령 허혈성 뇌졸중 또는 일과성 허혈 발작을 갖는 대상체에서의 혈압 조절을 위한 약학적 조성물
KR20220162456A (ko) 2021-06-01 2022-12-08 주식회사 보령 고혈압을 동반한 당뇨병성 신장질환의 예방 또는 치료용 약학적 조성물
KR20240146734A (ko) 2023-03-30 2024-10-08 (주) 에프엔지리서치 피마살탄의 신규 염 및 이의 제조방법

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5100897A (en) 1989-08-28 1992-03-31 Merck & Co., Inc. Substituted pyrimidinones as angiotensin ii antagonists
US5014228A (en) 1989-09-21 1991-05-07 Schlumberger Technologies, Inc. Method and apparatus for calibrating linear delay lines
JPH04120072A (ja) * 1990-09-11 1992-04-21 Meiji Seika Kaisha Ltd アンジオテンシン２拮抗性ピリミジン誘導体
EP0481614A1 (en) 1990-10-01 1992-04-22 Merck & Co. Inc. Substituted pyridopyrimidinones and related heterocycles as angiotensin II antagonists
EP0550313A1 (fr) 1991-12-30 1993-07-07 Synthelabo Nouveaux dérivés de 2-(tétrazol-5-yl)-(1,1'-biphényle), leur préparation et leur utilisation comme intermédiaires de synthèse
FR2688505B1 (fr) 1992-03-16 1994-05-06 Synthelabo Nouveau procede de preparation de 4-pyrimidinones.
FR2700543B1 (fr) * 1993-01-15 1995-03-17 Synthelabo Sels de dérivés de 4-pyrimidinone, leur préparation et leur application en thérapeutique.
JPH07157485A (ja) * 1993-12-02 1995-06-20 Nkk Corp 縮合ピリミジノン誘導体及びそれらを含有するアンジオテンシンｉｉ拮抗剤
KR100300566B1 (ko) 1994-09-17 2001-11-22 조생현 피리미디논유도체와그의제조방법및용도

Also Published As

Publication number Publication date
CN1266428A (zh) 2000-09-13
KR100354654B1 (ko) 2002-09-30
WO1999055681A1 (en) 1999-11-04
KR20010013626A (ko) 2001-02-26
BR9906373B1 (pt) 2010-11-16
DE69909209T2 (de) 2004-06-03
KR19990081093A (ko) 1999-11-15
EP0991627B1 (en) 2003-07-02
EP0991627A1 (en) 2000-04-12
RU2233278C9 (ru) 2009-11-27
CA2295446A1 (en) 1999-11-04
DE69909209D1 (de) 2003-08-07
CA2295446C (en) 2009-01-06
AU753424B2 (en) 2002-10-17
CN1195741C (zh) 2005-04-06
ES2209421T3 (es) 2004-06-16
RU2233278C2 (ru) 2004-07-27
JP3351539B2 (ja) 2002-11-25
US6294542B1 (en) 2001-09-25
ID29295A (id) 2001-08-16
AU3443899A (en) 1999-11-16
JP2001508469A (ja) 2001-06-26

Similar Documents

Publication Publication Date Title
BR9906373A (pt) Compostos pirimidinona, composições farmacêuticas contendo os compostos e processos para a preparação dos mesmos
BR9914360A (pt) N-aralquilaminotetralinas como ligandos para oreceptor neuropeptìdeo yy5
BR0207910A (pt) HidantÈnios e sua utilização no tratamento do diabetes
BR0000003A (pt) Azalidas e métodos de preparação das mesmas
BR0209957A (pt) Composto, processo para a preparação de um composto, composição farmacêutica que compreende um composto, utilização desse composto e processo para o tratamento e profilaxia de artrite, diabetes, distúrbios alimentares e obesidade
BR9712523A (pt) Novos derivados de pirazol heterociclilmetil-substituìdos
BR0113710A (pt) Compostos, processo para a preparação e utilização dos mesmos, composição farmacêutica, processo para o tratamento e profilaxia de artrite, enfermidades cardiovasculares, diabetes, insuficiência renal, distúrbios alimentares e obesidade
ZA992951B (en) N-substituted aminotetralins as ligands for the neuropeptide Y Y5 receptor useful in the treatment of obesity and other disorders.
BR0215777A (pt) Composto, método para preparar o mesmo, composição farmacêutica para prevenir e tratar cardioisquemia, cerebroisquemia, oclusão arterial cerebral e para melhorar microcirculação do cérebro, e uso do composto
ME00520B (me) Levodop/karbidop/entakapon farmaceutski preparat
BRPI9810519A (pt) derivados de 4&#39;&#39;-substituído-9-desoxo-9a-aza-9a-homoeritromicina a e composição farmacêutica compreendendo os mesmos.
AR024227A1 (es) Pirimidinas inhibidoras de replicacion de hiv, un proceso para su preparacion, el uso de las mismas para la manufactura de un medicamento, composiciones farmaceuticas, y un proceso para prepararlas
EA200400664A1 (ru) Фармацевтические композиции, включающие метформин и глибенкламид, применяемые для лечения сахарного диабета типа ii
SE0001899D0 (sv) New compounds
DE60236541D1 (de) Inhibitoren von 11-beta-hydroxysteroiddehydrogenase typ 1
WO2002088100A3 (de) Deuterierte 3-piperidinopropiophenone sowie diese verbindungen enthaltende arzneimittel
BR0010076A (pt) Inibidores de renina
BR9910179A (pt) Composto, composição farmacêutica, uso de um composto, e, processo para tratar uma doença ou condição mediada por fator xa em um animal de sangue quente
BR0207872A (pt) Composto para liberar agentes ativos, composição, forma de unidade de dosagem e método de administração
BR9801150A (pt) Derivados de propanolamina, processos para a preparação deles, produtos farmacêuticos compreendendo esses compostos e uso dos mesmos.
BR0111279A (pt) Derivados da ciclohexilamina como antagonistas para o receptor do nmda seletivo ao subtipo
BR0115045A (pt) Compostos, processo para sua preparação, composição farmacêutica que compreende os mesmos, sua utilização, processo para o tratamento e profilaxia de artrite, diabetes, distúrbios alimentares e obesidade
BR9916887A (pt) Uso de derivados de pirimidina
FI972434A (fi) Lamotrigiiniä sisältävä farmaseuttinen koostumus
BRPI0417946A (pt) composto, métodos para o tratamento ou a profilaxia de uma doença ou condição, e de distúrbios, e para a indução da cessação do hábito de fumar, composição farmacêutica, e, uso de um composto

Legal Events

Date Code Title Description
B07A Technical examination (opinion): publication of technical examination (opinion) [chapter 7.1 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: ALTERADA DE INT.CL: C07C 323/25, C07D 239/36, C07D 403/10, C07D 403/04, A61K 31/505, A61P 9/00

Ipc: C07C 323/25 (2008.04), C07D 239/36 (2008.04), C07D

B06A Notification to applicant to reply to the report for non-patentability or inadequacy of the application [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 16/11/2010, OBSERVADAS AS CONDICOES LEGAIS.

B21A Expiry acc. art. 78, item i of ipl- expiry of the term of protection

Free format text: PATENTE EXTINTA EM 16.11.2020